Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2025 · 10-Q
Revenue$75.00K$75.00K+4.2% vs Q2 2024 Net Income-$100.74M-$100.74MN/M vs Q2 2024 EPS, diluted—
Operating Income-$106,767,000N/M Operating Cash Flowderived-$75,373,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$75,415,000N/M Margins · derivedOperating margin-142356.0%−42096.3 pt vs Q2 2024
Net margin-134313.3%−44045.3 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 6, 2025 · 37 d after period end